Ovarian cancer

Byaibio

Ovarian cancer is a highly heterogeneous gynecological malignancy and one of the most common gynecologic cancers, with substantial cancer-related morbidity and mortality. It has been studied as a radiogenomics target, where imaging phenotypes are correlated with molecular biomarkers such as BRCA mutations, homologous recombination deficiency, and immune-related markers. Mechanistically, the disease involves tumor-promoting pathways including s1pr1-driven tumorsphere proliferation and metastasis, platelet-induced vista upregulation, and immunologic remodeling of the tumor microenvironment. Immune contexture is clinically relevant, with associations reported for m0 macrophage, m2 macrophage, and neutrophil infiltration, while peptide-based immunotargeting and nk 92 cell therapy are being explored as therapeutic strategies. Recent studies also emphasize ascites-associated proliferation and metastasis, as well as prognostic immune states linked to adverse clinical features and survival. Overall, ovarian cancer research is increasingly integrating imaging, immune profiling, and xenograft models to identify biomarkers and improve treatment response.

Radiogenomics and Biomarkers

  • A radiogenomics study used imaging phenotypes to correlate with molecular biomarkers in ovarian cancer, including BRCA mutations, homologous recombination deficiency, and immune-related biomarkers (PMID:41192450).
  • The disease was highlighted as a highly heterogeneous gynecological malignancy, supporting the use of imaging-based stratification for molecular subtyping (PMID:41192450).
  • A 2026 RoFo review placed ovarian cancer among gynecologic cancers where radiogenomics may help connect phenotype with genotype for biomarker discovery (PMID:41192450).

Tumor Progression and Metastasis

  • s1pr1 was reported to promote ovarian cancer tumorsphere proliferation and metastasis, linking sphingosine-1-phosphate signaling to aggressive behavior (PMID:41958014).
  • The ascites environment was used to study tumorsphere proliferation and metastatic growth in ovarian cancer, underscoring the role of the peritoneal microenvironment (PMID:41958014).
  • Platelet-mediated regulation of vista was investigated as a mechanism shaping the ovarian tumor microenvironment and potentially enhancing immune evasion (PMID:41841642).

Immune Microenvironment and Prognosis

  • Higher m0 macrophage levels predicted improved outcomes in ovarian cancer, suggesting a favorable immune-associated prognostic signal (PMID:42008432).
  • m2 macrophage abundance was associated with vascular invasion, persistent tumor, and worse survival, consistent with an immunosuppressive phenotype (PMID:42008432).
  • Neutrophil infiltration correlated with poor survival, and elevated vista levels were associated with poorer clinical outcomes (PMID:42008432; PMID:41841642).
  • An immune-cell profiling study identified immunosuppressive states associated with adverse clinical attributes and survival times in ovarian cancer (PMID:42008432).

Therapeutic Strategies

  • Peptide-based immunotargeting was discussed as a next-generation strategy for gynecologic cancers, including ovarian cancer (PMID:41930712).
  • nk 92 administration was evaluated in early and established ovarian cancer xenograft models, with intraperitoneal delivery improving survival (PMID:42008496).
  • The NK-92 study supports cell-based immunotherapy as a potential anti-cancer approach in ovarian cancer preclinical models (PMID:42008496).